Adalimumab Mechanism of Action: How Adalimumab Works | Elicit

Adalimumab Mechanism of Action

How Adalimumab (Humira) Works: TNF-α neutralization by preventing TNF-α binding to p55/p75 receptors.

Last updated: March 2026

Quick Summary

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody that acts as a tumor necrosis factor (TNF) blocker. It binds TNF-α and prevents interaction with TNF receptors (p55/p75), helping reduce the inflammatory cascade. Clinically, it is indicated for multiple immune-mediated diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Properties

Details
Generic Name adalimumab
Brand Names Humira
Drug Class Tumor necrosis factor (TNF) inhibitor (TNF blocker); recombinant human IgG1 monoclonal antibody
Primary Target Tumor necrosis factor alpha (TNF-α)
Approved Indications Moderate-to-severe rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult and pediatric Crohn's disease, ulcerative colitis, moderate-to-severe plaque psoriasis, hidradenitis suppurativa, uveitis
Key Effect Blocks TNF-α, preventing it from binding to p55 and p75 receptors and reducing inflammatory signaling

Development History

Adalimumab was developed by BASF Pharma (later Knoll Pharmaceutical) in partnership with Cambridge Antibody Technology (CAT), beginning in 1993 when BASF commissioned CAT to produce a TNF-neutralizing human antibody using the then-nascent phage display technology. Within two years, the lead compound designated D2E7 had been identified. Unlike the earlier anti-TNF agents infliximab (chimeric, ~33% murine) and CDP571 (humanized, ~95% human), D2E7 was engineered as a fully human recombinant IgG1 monoclonal antibody with no non-human or artificially fused sequences, a design choice intended to minimize immunogenicity and the formation of anti-drug antibodies that had been observed with chimeric constructs. The binding specificity was derived by transferring the high-affinity neutralization potency of a murine anti-TNF antibody into a fully human IgG1 scaffold, yielding a molecule that selectively blocks both p55 and p75 TNF-α receptors on human cells. The 40 mg subcutaneous every-other-week dosing schedule was selected during phase II, with the 40 mg and 80 mg doses showing equivalent clinical benefit and establishing a regimen offering improved convenience relative to the more frequent administration schedules of then-available biologics.

The pivotal approval program for rheumatoid arthritis comprised the ARMADA trial, a 24-week randomized, double-blind, placebo-controlled study enrolling 271 patients with active RA who had an inadequate response to methotrexate. The primary endpoint was ACR20 response at week 24; adalimumab 40 mg plus MTX achieved an ACR20 of 67.2% versus 14.5% for placebo plus MTX. The ACR50 response of 55.2% at the 40 mg dose further supported differentiation from placebo. STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) enrolled 636 RA patients on standard antirheumatic therapy and demonstrated ACR20 of 52.8% for adalimumab versus 34.9% for placebo at 24 weeks, with no statistically significant differences in adverse event rates, serious adverse events, or serious infections between arms. On the basis of these trials and additional DE019 data showing inhibition of radiographic progression, the FDA approved adalimumab on December 31, 2002, under the brand name Humira for moderately to severely active RA with inadequate DMARD response. The European Medicines Agency followed with approval in September 2003.

Adalimumab's label expanded across six additional immune-mediated indications over the subsequent decade. Psoriatic arthritis and ankylosing spondylitis approvals followed the RA launch; for ankylosing spondylitis, the ATLAS trial demonstrated significant reduction in signs and symptoms versus placebo in patients with inadequate NSAID response. Adult Crohn's disease was added in 2007, followed by plaque psoriasis in 2008, based on trials showing induction and maintenance of remission and PASI response, respectively. Polyarticular juvenile idiopathic arthritis received approval in 2008 for patients aged 4 and older and was later extended to patients 2 years and older in 2014. Ulcerative colitis was added in 2012, making adalimumab the only agent then approved for both primary inflammatory bowel disease indications. Pediatric Crohn's disease followed in 2014, and subsequent label work added hidradenitis suppurativa (2015), uveitis (2016), and pediatric uveitis (2019). The current Humira label covers more than ten distinct indications spanning rheumatologic, dermatologic, gastroenterologic, and ophthalmologic disease, and since 2023 the reference molecule has faced biosimilar competition in the United States from multiple approved adalimumab biosimilars including Amjevita (adalimumab-atto, Amgen).

Detailed Mechanism of Action

Subcutaneous absorption and tissue distribution. Adalimumab is administered by subcutaneous injection and reaches peak serum concentrations in approximately five days, with an absolute bioavailability of roughly 64%. Its approximately 14-day elimination half-life reflects FcRn-mediated IgG recycling in endothelial cells, enabling every-other-week dosing. As an IgG1 antibody, it distributes predominantly to vascular and extracellular fluid compartments, with measurable penetration into inflamed synovial fluid, intestinal mucosa, and psoriatic skin lesions.

Primary target engagement. Adalimumab is a fully human IgG1 monoclonal antibody that neutralizes TNF-α by binding TNF-α and thereby obstructing productive TNF–TNF receptor engagement. The crystal structure of the TNF-α–adalimumab Fab complex at 3.1 Å resolution reveals that the antibody engages a discontinuous epitope across TNF-α protomers via both heavy- and light-chain CDRs, burying 2,540 Ų of surface area. Critically, this epitope directly overlaps the TNF receptor-binding site, and the structural data show that adalimumab prevents ligands from binding to TNFR2, blocking receptor engagement by steric occlusion. In addition to soluble TNF, adalimumab binds cell-surface transmembrane TNF-α, having been shown to be bound to transmembrane TNF-α on TNF-expressing cells, enabling blockade at the membrane level. The full-length IgG1 also forms higher-order multivalent assemblies with the TNF trimer; electron microscopy reveals complex structures consisting of 1:1, 1:2, 2:2, and 3:2 adalimumab–TNF complexes, which increase functional avidity and promote durable TNF sequestration at inflammatory sites.

Downstream NF-κB suppression and transcriptional reprogramming. By disrupting TNF–TNFR signaling, adalimumab suppresses TNF-driven NF-κB transcriptional output. In U937 NF-κB reporter assays, TNF stimulation led to a 122-fold increase in NF-κB luciferase activity that was reduced to baseline by adalimumab. Consistent with this pathway-level effect, adalimumab normalizes TNF-induced expression of NF-κB-responsive adhesion molecules, lowering ICAM-1 surface expression to baseline at 16.7 nM. At the gene and chromatin level, adalimumab reverses LPS-induced upregulation of NF-κB-associated genes including IKBKB, IRAK1, TRAF2, MAP3K7, and TNFAIP3 in keratinocytes, with concordant protein-level changes. It also reshapes inflammatory microRNA patterns: anti-inflammatory miRNAs including miR-125b and miR-30a are restored while pro-survival miRNAs are downregulated, supporting broader normalization of TNF-coupled regulatory networks.

Th17-axis suppression. TNF blockade converges on Th17-associated cytokine programs. In Th17-polarized cells from healthy subjects and patients with rheumatoid arthritis, adalimumab suppresses IL-17A, IL-17F, and IL-22 production, accompanied by decreased phospho-p38, phospho-p65, phospho-STAT3, and RORγt levels, with decreased histone H3/H4 acetylation at the RORγt promoter region.

Fc-mediated effector functions. As an IgG1 antibody, adalimumab engages Fcγ receptors and promotes antibody-dependent and complement-dependent cytotoxic mechanisms against membrane TNF-bearing cells, with biosimilar data confirming similar Fcγ receptor binding and equivalent ADCC and CDC effector functions. Adalimumab induces complement-dependent cytotoxicity in mTNF-transfected cells with activity comparable to infliximab; certolizumab pegol, which lacks an Fc region, does not mediate either CDC or ADCC, confirming the requirement for an intact IgG1 Fc. An F(ab')₂ fragment retains the ability to trigger redox-linked signaling that is independent of the Fc portion of adalimumab and involves NADPH oxidase activation, indicating that some downstream outcomes derive from ligation-induced tmTNF signaling rather than Fc-mediated cytotoxic recruitment alone.

Reverse signaling through transmembrane TNF. Engagement of membrane TNF-α propagates outside-to-inside reverse signaling that reshapes immune-cell survival and turnover. In tmTNF-expressing Jurkat T-cell systems, adalimumab induces apoptosis and cell-cycle arrest via outside-to-inside transduction through transmembrane TNF-α, while monocytic contexts show caspase-3 activation in a caspase-dependent apoptosis program.

Clinical translation. These molecular and cellular events align with observed therapeutic benefit. After sequential injections in rheumatoid arthritis, adalimumab drives a progressive restoration of iTNF-α-positive CD14+ monocyte frequencies toward healthy-donor levels after 12 injections, reflecting durable remodeling of TNF-axis immune biology. Loss of response in some patients reflects immunogenicity: neutralizing anti-adalimumab antibodies abolish TNF blockade and abolish the restoration of iTNF-α+ monocyte frequencies, directly linking molecular target engagement to the observed clinical outcome.

Clinical Relevance

Approved Indications

Key Drug Interactions (Mechanism-Based)

Black Box Warnings

Emerging Indications

Nephrology

Hepatology

Immunology

Neurology

Psychiatry / Substance Use

Clinical Trials of Adalimumab

Trial Name Phase Design N Enrolled Intervention Indication Primary Endpoint Key Result Status
VISUAL III 3 Active and Inactive Non-infectious Uveitis 424 Adalimumab 40 mg every other week in an open-label extension study for patients from the VISUAL I/II trials. Long-term safety and disease quiescence At week 150, the rate of quiescence increased from 34% at baseline to 85%. Corticosteroid-free quiescence was achieved by 54% of patients with active uveitis at baseline and 89% with inactive uveitis at baseline. The mean daily corticosteroid dose was reduced from 9.4 mg/day at baseline to 1.5 mg/day at week 150. Completed
STRIVE 4 Polyarticular-course Juvenile Idiopathic Arthritis (JIA) 838 Adalimumab (with or without methotrexate) vs. methotrexate alone. Evaluation of long-term safety of adalimumab with or without methotrexate At the 7-year analysis, the rate of serious infections was 2.0 events per 100 patient-years in the adalimumab ± methotrexate arm, compared to 1.5 events per 100 patient-years in the methotrexate alone arm. No deaths or malignancies were reported. Ongoing
VISUAL II 3 Inactive Non-infectious Uveitis 229 Adalimumab (80 mg loading dose, then 40 mg every 2 weeks) or placebo, with a mandatory prednisone taper. Time to treatment failure, a composite endpoint including uveitic flare and visual acuity loss. Adalimumab significantly reduced the risk of treatment failure by 43% compared to placebo (HR 0.57; 95% CI, 0.39-0.84; p=0.004). The median time to treatment failure was 8.3 months for placebo and was not reached (>18 months) for adalimumab. Completed
VISUAL I 3 Active Non-infectious Uveitis 217 Adalimumab (80 mg loading dose, then 40 mg every 2 weeks) or placebo, with a mandatory prednisone taper. Time to treatment failure, a composite endpoint of uveitic flare and visual acuity loss. Adalimumab reduced the risk of treatment failure by 50% compared to placebo (HR 0.50; 95% CI 0.36-0.70; p<0.001). The median time to treatment failure was 24 weeks for the adalimumab group versus 13 weeks for the placebo group. Completed
SYCAMORE 3 Juvenile Idiopathic Arthritis-Associated Uveitis 90 Adalimumab (20 mg or 40 mg based on weight) or placebo, both with background methotrexate. Time to treatment failure based on Standardisation of Uveitis Nomenclature (SUN) criteria. The trial was stopped early for efficacy. Adalimumab plus methotrexate reduced the risk of treatment failure by 75% compared to placebo plus methotrexate (HR 0.25; 95% CI, 0.12-0.49; p<0.0001). Completed
PIONEER II 3 Hidradenitis Suppurativa 326 Adalimumab 40 mg weekly or placebo for 12 weeks. Clinical response (HiSCR), defined as ≥50% reduction in inflammatory nodules and abscesses with no increase in abscesses or draining fistulas. At week 12, the rate of clinical response (HiSCR) was significantly higher in the adalimumab group compared to placebo (58.9% vs. 27.6%; P<0.001). Completed
PIONEER I 3 Hidradenitis Suppurativa 307 Adalimumab 40 mg weekly or placebo for 12 weeks. Clinical response (HiSCR), defined as at least a 50% reduction in total abscess and inflammatory-nodule count with no increase in abscesses or draining fistulas. At week 12, a significantly higher proportion of patients in the adalimumab group achieved clinical response (HiSCR) compared to placebo (41.8% vs. 26.0%; P=0.003). Completed
ABILITY-1 3 Nonradiographic Axial Spondyloarthritis (nr-axSpA) 185 Adalimumab 40 mg every other week or placebo for 12 weeks, followed by a 144-week open-label extension. Proportion of patients achieving an ASAS40 response at week 12. At week 12, 36% of adalimumab-treated patients achieved an ASAS40 response versus 15% of placebo-treated patients (p<0.001). At year 3, 46% of patients initially receiving adalimumab achieved ASDAS inactive disease. Completed

Adalimumab Competitive Landscape

This table shows how Adalimumab compares to other TNF inhibitors and biologic therapies for immune-mediated inflammatory diseases. Each entry breaks down the representative drugs, their molecular targets, and how they actually work in the body.

Drug Class Representative Drug(s) Primary Molecular Target Mechanism of Action Key Efficacy Outcomes Route & Dosing Safety / Risk Profile Key Limitations
TNF inhibitors Adalimumab (Humira), Infliximab (Remicade), Etanercept (Enbrel) Tumor necrosis factor-alpha (TNF-alpha) Binds specifically to tumor necrosis factor-alpha (TNF-alpha) and blocks its interaction with cell surface TNF receptors, thereby neutralizing its pro-inflammatory activity. In rheumatoid arthritis trials, adalimumab achieved an ACR20 response rate of 46% at 6 months versus 19% for placebo. In psoriatic arthritis, etanercept achieved an ACR20 at Month 3 of 62% vs 23% with placebo. In ulcerative colitis, golimumab achieved clinical remission at Week 6 in 18% of patients versus 6% for placebo. Subcutaneous injection, typically every other week or weekly, or intravenous (IV) infusion every 1-2 months. Carries a boxed warning for increased risk of serious infections (like tuberculosis and bacterial sepsis) and malignancies (like lymphoma). Common adverse reactions include upper respiratory infections, injection site reactions, headache, and rash. Effectiveness can decrease over time as some patients develop anti-drug antibodies that neutralize the treatment. The effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant of other TNF blockers.
IL-17 inhibitors Secukinumab (Cosentyx), Ixekizumab (Taltz), Bimekizumab (Bimzelx) Interleukin-17A (IL-17A), Interleukin-17F (IL-17F), or the IL-17 receptor Binds to and neutralizes IL-17 cytokines (e.g., IL-17A, IL-17F) or blocks the IL-17 receptor, inhibiting the release of proinflammatory cytokines and chemokines. In plaque psoriasis, IL-17 inhibitors demonstrate high efficacy, with PASI 90 rates at Week 12-16 ranging from approximately 59% to 91%. In a head-to-head trial (IXORA-S), ixekizumab showed superior PASI 90 rates compared to ustekinumab at 52 weeks (76.5% vs 59.0%). Subcutaneous injection, with a loading dose phase followed by maintenance dosing every 2 to 8 weeks, depending on the agent. Most common adverse reactions include nasopharyngitis, upper respiratory tract infections, and injection site reactions. The class is associated with an increased risk of mucocutaneous candidiasis and may cause exacerbation or new onset of inflammatory bowel disease. Not recommended for patients with active inflammatory bowel disease due to risk of exacerbations. Dosing is generally more frequent than for IL-12/23 or some IL-23 inhibitors.
IL-23 (p19) inhibitors Guselkumab (Tremfya), Risankizumab (Skyrizi), Tildrakizumab (Ilumya) p19 subunit of Interleukin-23 (IL-23) Selectively bind to the p19 subunit of the IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and blocking the downstream signaling pathway that promotes Th17 cell-mediated inflammation. In plaque psoriasis (VOYAGE 1 trial), guselkumab was superior to adalimumab at week 16, with higher PASI 90 (73.3% vs 49.7%) and PASI 100 (37.4% vs 17.1%) response rates. In psoriatic arthritis (DISCOVER-1 & 2 trials), guselkumab achieved significantly higher ACR20 response rates at week 24 versus placebo (52-64% vs 22-23%). Subcutaneous injection with initial loading doses, followed by maintenance dosing every 8 or 12 weeks. Generally well-tolerated with a favorable safety profile. The most common adverse events include upper respiratory tract infections, headache, and injection site reactions. Serious adverse events like severe infections and malignancy have been infrequent in clinical trials. While highly effective for psoriasis, the evidence base for psoriatic arthritis and IBD is less extensive than that for TNF inhibitors. Direct head-to-head data against adalimumab in psoriatic arthritis are limited, making their relative positioning less clear for patients with predominantly joint disease.
IL-12/23 (p40) inhibitors Ustekinumab (Stelara) p40 subunit of IL-12 and IL-23 Binds to the p40 protein subunit shared by both the IL-12 and IL-23 cytokines, preventing them from binding to their cell surface receptors and thus disrupting their inflammatory signaling pathways. In patients with Crohn's disease who previously failed anti-TNF therapy, ustekinumab maintenance therapy resulted in significantly higher rates of clinical response (69.4% vs 42.5% for placebo) and remission (41.7% vs 27.4% for placebo). While effective in psoriasis, some evidence suggests selective IL-23 inhibitors may be more effective for skin outcomes. A single weight-based intravenous (IV) induction dose, followed by subcutaneous (SC) maintenance injections, typically every 8 or 12 weeks. Adverse events can include serious infections, malignancies, and major adverse cardiovascular events (MACEs), which prompted specific safety monitoring in earlier psoriasis trials. Overall, the long-term safety profile is generally considered favorable. Efficacy is limited in patients who are primary non-responders to TNF inhibitors in Crohn's disease. Its use is not recommended for axial spondyloarthritis, as responses are considered better for peripheral joint involvement.
JAK inhibitors Tofacitinib (Xeljanz), Upadacitinib (Rinvoq), Filgotinib (Jyseleca) Intracellular Janus kinases (JAK1, JAK2, JAK3, TYK2) Blocks the JAK-STAT signaling pathway, which transmits signals from cytokines and growth factors, thereby preventing the phosphorylation of STATs and reducing inflammatory gene expression. In ulcerative colitis, upadacitinib induction (45 mg) achieved clinical remission in 26-33% of patients vs 5-7% for placebo. In Crohn's disease, upadacitinib induction (45 mg) achieved clinical remission in 39-50% vs 21-29% for placebo. Real-world data suggests upadacitinib has higher odds of achieving clinical response and remission in UC vs ustekinumab. Oral tablets or solution, taken once or twice daily. Carries a class-wide boxed warning for serious infections, increased mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Common adverse reactions include upper respiratory tract infections, nausea, headache, and herpes zoster. Not recommended for use with biologic DMARDs or other potent immunosuppressants. Safety concerns and boxed warnings may limit use to patients who have failed other therapies, such as TNF inhibitors.
IL-6 receptor inhibitors Tocilizumab (Actemra), Sarilumab (Kevzara) Interleukin-6 Receptor (IL-6R) Monoclonal antibodies that bind to and inhibit both soluble and membrane-bound interleukin-6 receptors (IL-6R), preventing IL-6 from exerting its pro-inflammatory effects. In RA patients with an inadequate response to TNF inhibitors (RADIATE trial), tocilizumab (8 mg/kg) plus methotrexate achieved a significantly higher ACR20 response rate at 24 weeks compared to placebo (50.0% vs 10.1%). In biologic-naïve patients, some head-to-head trials have shown IL-6 inhibitors to be more efficacious than adalimumab. Intravenous (IV) infusion every 4 weeks or subcutaneous (SC) injection weekly or every 2 weeks, depending on the agent. Common adverse events include infections (especially upper respiratory), gastrointestinal symptoms, and injection site reactions. Can cause laboratory abnormalities such as neutropenia, elevated liver enzymes, and dyslipidemia. Boxed warnings typically cover the risk of serious infections. Not approved for psoriatic arthritis or inflammatory bowel disease, limiting their utility compared to adalimumab in patients with those comorbidities. Real-world studies in b/ts-experienced RA patients have shown no significant difference in outcomes compared to TNF inhibitors, contrasting with RCT data in biologic-naïve patients.

Open Research Questions

What mechanisms drive loss of response after initial benefit, and why do predictors differ between adalimumab and infliximab?

Roughly a third of Crohn's disease patients lose response by year 3 of anti-TNF therapy, and predicting who is at risk would change induction dosing and immunomodulator choices. The PANTS 3-year cohort showed that low week-14 drug concentrations predict loss of response, while HLA-DQA1*05 carriage predicts immunogenicity for infliximab but not adalimumab, a divergence corroborated by a mechanistic analysis of HLA-DQA1*05 binding differences between the two molecules - leaving the predictors of adalimumab-specific immunogenicity unresolved.

To what extent does proactive therapeutic drug monitoring improve clinical outcomes over reactive monitoring or empiric dosing?

If proactive TDM materially improved remission rates it would justify routine assay use, but the evidence base remains contested. A 2024 systematic review and meta-analysis found that proactive TDM was numerically but not statistically superior to reactive TDM or conventional management for sustaining remission, while a 213-case IBD precision-dosing program reported that trough concentrations below 10 μg/mL conferred a 23.7-fold higher likelihood of therapy intensification, suggesting clinical utility that randomized trials have yet to confirm.

Which baseline biomarkers reliably identify patients destined for primary non-response to adalimumab?

Approximately 40% of TNFi recipients discontinue for non-response or adverse events, and an actionable pre-treatment signature would spare months of failed therapy. A machine-learning analysis of whole-blood transcriptomics in rheumatoid arthritis identified candidate predictive gene-expression features for adalimumab response, but external validation, cross-indication generalizability, and integration with clinical predictors remain open.

How safe is repeated multi-switching between the adalimumab originator and biosimilars over long-term horizons?

Non-medical switching is now common, but cumulative immunogenicity and drug-survival effects of multiple switches are poorly characterized. A phase 3 interchangeability extension in psoriasis reported comparable efficacy, safety, and immunogenicity after repeated switching between CT-P17 and EU reference adalimumab, and a multinational psoriasis cohort found no difference in drug survival or safety between biosimilars and originator over five years, though indications outside dermatology and patients undergoing three or more switches remain under-studied.

Does third-trimester adalimumab exposure increase serious infection risk in infants, and how should dosing be timed?

Adalimumab crosses the placenta efficiently in late gestation, raising concerns about neonatal immunosuppression that influence whether dosing should be held in the third trimester. A 56,866-offspring MarketScan analysis found no overall increase in serious infections with in-utero TNFi exposure, but a 70% higher risk with third-trimester exposure and a signal toward higher-placental-transfer agents - directional but imprecise estimates that future cohorts must confirm before guidelines update.

Research Adalimumab with Elicit — Free

This mechanism of action page was generated using Elicit's AI research agent, which synthesizes explanations from peer-reviewed pharmacology literature. Every pathway description and citation is traceable — because in pharmacology, accuracy isn't optional.

Try these searches on Elicit: